SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Chemours Co – ‘8-K’ for 3/5/21

On:  Wednesday, 3/10/21, at 4:15pm ET   ·   For:  3/5/21   ·   Accession #:  1564590-21-12062   ·   File #:  1-36794

Previous ‘8-K’:  ‘8-K’ on 3/2/21 for 3/1/21   ·   Next:  ‘8-K’ on / for 3/22/21   ·   Latest:  ‘8-K’ on / for 5/3/21

Magnifying glass tilted right emoji
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/10/21  Chemours Co                       8-K:8,9     3/05/21   12:383K                                   ActiveDisclosure/FA

Current Report   —   Form 8-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     32K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     31K 
 3: EX-99.2     Miscellaneous Exhibit                               HTML     66K 
 8: R1          Document and Entity Information                     HTML     46K 
10: XML         IDEA XML File -- Filing Summary                      XML     12K 
 7: XML         XBRL Instance -- cc-8k_20210305_htm                  XML     14K 
 9: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 5: EX-101.LAB  XBRL Labels -- cc-20210305_lab                       XML     56K 
 6: EX-101.PRE  XBRL Presentations -- cc-20210305_pre                XML     34K 
 4: EX-101.SCH  XBRL Schema -- cc-20210305                           XSD     19K 
11: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    19K 
12: ZIP         XBRL Zipped Folder -- 0001564590-21-012062-xbrl      Zip     40K 

‘8-K’   —   Current Report

This is an HTML Document rendered as filed.  [ Alternative Formats ]

 iX:   C:   C:   C:   C:   C:   C: 
 i false  i 0001627223 0001627223 2021-03-05 2021-03-05








FORM  i 8-K






 i March 5, 2021

Date of Report (Date of Earliest Event Reported)

 i The Chemours Company

(Exact Name of Registrant as Specified in Its Charter)


 i Delaware


 i 001-36794


 i 46-4845564

(State or Other Jurisdiction




(I.R.S. Employer

Of Incorporation)


File Number)


Identification No.)


 i 1007 Market Street

 i Wilmington,  i Delaware  i 19801

(Address of principal executive offices)


Registrant’s telephone number, including area code:  i (302)  i 773-1000


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class


Trading Symbol(s)


Name of Exchange on Which Registered

 i Common Stock ($0.01 par value)


 i CC


 i New York Stock Exchange



Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company




If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.







Item 8.01. Other Events.


On March 5, 2021, The Chemours Company AR, LLC, a Delaware limited liability company (“Chemours AR”), and The Chemours Company FC, LLC, a Delaware limited liability company (“Chemours FC”), entered into an amendment (the “First Amendment”) to its Amended and Restated Receivables Purchase Agreement, dated as of March 9, 2020. Chemours AR and Chemours FC entered into the First Amendment with The Toronto-Dominion Bank, as Administrative Agent, as LC Bank, as a Group Agent, and as a Related Committed Purchaser, and Reliant Trust, as a Conduit Purchaser. Chemours FC is a wholly-owned subsidiary of The Chemours Company, a Delaware corporation (the “Company”), and Chemours AR is a wholly-owned, bankruptcy-remote special purpose subsidiary of Chemours FC.


The First Amendment, among other things, extends the term of the Amended and Restated Receivables Purchase Agreement (as amended by the First Amendment), such that Chemours AR may sell certain receivables and request investments and letters of credit until the earlier of March 6, 2023 or another event that constitutes a “Termination Date” under the Amended and Restated Receivables Purchase Agreement (as amended by the First Amendment). Prior to giving effect to the First Amendment, the Amended and Restated Receivables Purchase Agreement was scheduled to expire on March 5, 2021. The First Amendment also increases the Facility Limit under the arrangement from $125 million to $150 million.


The foregoing description is only a summary of the First Amendment, and is qualified in its entirety by reference to the full text of the First Amendment, which is filed as Exhibit 99.1 hereto, respectively, and which is incorporated by reference herein.


Item 9.01. Financial Statements and Exhibits.






First Amendment to Amended and Restated Receivables Purchase Agreement, dated as of March 5, 2021.

Exhibit A to the First Amendment to Amended and Restated Receivables Purchase Agreement, dated as of March 5, 2021.


The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.



* Certain schedules and exhibits to Exhibit 99.1 have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of such schedules and exhibits, or any section thereof, to the Securities and Exchange Commission upon request.




Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.







/s/ Sameer Ralhan



Sameer Ralhan



Senior Vice President, Chief Financial







March 10, 2021





Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on:3/10/21
For Period end:3/5/21
 List all Filings 
Filing Submission 0001564590-21-012062   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2021 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., May 15, 7:21:41.1am ET